HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Natalizumab is effective in controlling the inflammatory rebound after its discontinuation and failure of an alternative treatment.

Abstract
Progressive multifocal leukoencephalopathy (PML) is the most feared complication when natalizumab (NAT) is used in the treatment of relapsing multiple sclerosis (MS). JC virus serologic status is a currently established risk factor for PML. When seroconversion occurs, NAT discontinuation should be based on a solid rationale to avoid an MS inflammatory resurgence. The JC virus index value may also provide further useful information to help practitioners and patients in their decision process.
AuthorsBruno Barroso, Marie Miquel, Raluca Marasescu, Stéphanie Demasles, Elsa Krim, Mikael Bonnan
JournalMultiple sclerosis and related disorders (Mult Scler Relat Disord) Vol. 4 Issue 4 Pg. 380-2 (Jul 2015) ISSN: 2211-0356 [Electronic] Netherlands
PMID26195060 (Publication Type: Case Reports, Journal Article)
CopyrightCopyright © 2015 Elsevier B.V. All rights reserved.
Chemical References
  • Antibodies, Viral
  • Immunologic Factors
  • Natalizumab
Topics
  • Adult
  • Antibodies, Viral (blood)
  • Humans
  • Immunologic Factors (therapeutic use)
  • JC Virus (immunology)
  • Male
  • Multiple Sclerosis, Relapsing-Remitting (drug therapy, immunology, pathology)
  • Natalizumab (therapeutic use)
  • Retreatment

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: